News & Views
Agreement to push Antibody Development forward
Oct 28 2022
International Biotech Genmab has been granted a licencing agreement to progress Scancell’s investigational anti-glycan monoclonal antibody into multiple novel therapeutic products.
The agreement grants Genmab the exclusive right to develop and commercialise the humanised antibody for any and all potential disease areas, excluding cell therapy applications. Scancell will be eligible to receive an upfront payment as well as potential milestone payments, of up to $208 million for each product developed and commercialised, up to a maximum of $624 million, if Genmab develops and commercialises products across all defined modalities. It will also receive low single digit royalties on net sales of products.
Developed on the company’s anti-cancer GlyMab® platform the anti-glycan monoclonal antibody is one of five currently in Scancell’s antibody portfolio, providing a rich reservoir of potential products for its own in house clinical development and also for further deals.
Prof Lindy Durrant, Chief Executive Officer, Scancell, commented: “This license agreement with Genmab provides strong validation for our proprietary GlyMab® platform and our ability to utilise this technology to support the creation of novel, differentiated antibody products. Genmab is a leader in the field of antibody therapies for cancer and we are very pleased to be working with them to progress this novel antibody product through clinical development and commercialisation.”
More information online
Digital Edition
Lab Asia 31.6 Dec 2024
December 2024
Chromatography Articles - Sustainable chromatography: Embracing software for greener methods Mass Spectrometry & Spectroscopy Articles - Solving industry challenges for phosphorus containi...
View all digital editions
Events
Nov 27 2024 Istanbul, Turkey
Jan 22 2025 Tokyo, Japan
Jan 22 2025 Birmingham, UK
Jan 25 2025 San Diego, CA, USA
Jan 27 2025 Dubai, UAE